Pudongia also continues its excellent launch trajectory with strong demand in both endemic and travel markets.

May 8, 2025 / receipt, needs a key / Christophe Weber, CEO | earnings call 2025-05-08 | transcript c4f58a88-c394-45af-b2ef-c75c08e4a14c | chars 4463-4573 | segment 4

Look, I think Kudenga is off for a strong start. We see a very significant demand where it is, I mean, in endemic countries as well as countries where there is a travel market. We are ramping up our manufacturing capacity. This is a limiting factor right now. The demand is way greater than our supply capacity. We are expanding this supply capacity. So, yeah, we are very pleased with the takeoff. I don't think there is any special phasing here. There will be in the future, by the way, because there is a private market that is quite predictable and linear, if you like, but more and more because we are going into public immunization programs, they are notoriously phased, if you like, depending on the order or the supply that we can provide to governments. But really, product is off to a fantastic start. And as we all know, dengue is a major issue in many countries.

Jul 31, 2024 / receipt, needs a key / Christophe, other | earnings call 2024-07-31 | transcript 58c4d7e0-a5ae-4b2d-8c27-151c101230a8 | chars 40917-41791 | segment 41

Right now, we are more in the private market and the travel market. And so I think the large volume type of demand will come later from endemic countries.

Feb 1, 2024 / receipt, needs a key / Christophe, other | earnings call 2024-02-01 | transcript c0f66767-d057-40d7-9210-239de57e810f | chars 59879-60033 | segment 62

CUDENGA is available in 17 European countries, and travel recommendations support its use to help protect travelers to dengue-endemic areas.

Feb 1, 2024 / receipt, needs a key / Christophe Weber, CEO | earnings call 2024-02-01 | transcript c0f66767-d057-40d7-9210-239de57e810f | chars 8032-8172 | segment 8

Our dengue vaccine, Scudenga, was recently approved in Argentina and Thailand, and we are pleased with the momentum we are seeing in both endemic and travel market.

Jul 27, 2023 / receipt, needs a key / Christophe Weber, CEO | earnings call 2023-07-27 | transcript 5f17419c-ea0f-4fdc-8063-fc5027f57dfd | chars 3256-3420 | segment 3

But on the flip side, we did see some underspend in travel and meetings and events, but they were about the same amount as the negative impact on the revenue for our neuroscience.

May 11, 2021 / receipt, needs a key / Costa, CFO | earnings call 2021-05-11 | transcript 433074af-8ad2-44f0-a154-042b1b83d555 | chars 24614-24793 | segment 25

585 Kendall, Cambridge

ir_statement / Sep 17, 2026 / receipt

Building unified digital infrastructure and the Lab of the Future at 585 Kendall with augmented ways of working

ir_statement / Sep 17, 2026 / receipt

Driving Efficiency with Real-Time Decision Support

ir_statement / Sep 17, 2026 / receipt

Shonan iPark, Japan

ir_statement / Sep 17, 2026 / receipt

Targeting Core Operating Profit margin improvement to reach low-to-mid 30s%

ir_statement / Sep 17, 2026 / receipt

Unleashing the power of data, digital & technology to boost efficiencies across the entire value chain

ir_statement / Sep 17, 2026 / receipt

Unleashing the power of data, digital & technology to boost efficiencies across the entire value chain

ir_statement / Sep 17, 2026 / receipt

Targeting Core Operating Profit margin improvement to reach low-to-mid 30s%

ir_statement / Sep 17, 2026 / receipt

Unleashing the power of data, digital & technology to boost efficiencies across the entire value chain

ir_statement / Sep 17, 2026 / receipt

585 Kendall, Cambridge

ir_statement / Sep 17, 2026 / receipt

Building unified digital infrastructure and the Lab of the Future at 585 Kendall with augmented ways of working

ir_statement / Sep 17, 2026 / receipt

Driving Efficiency with Real-Time Decision Support

ir_statement / Sep 17, 2026 / receipt